22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › KYMERA THERAPEUTICS INC. › 2024-2025

KYMERA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 27, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 193Asset managers, any item
  • 1,039Fund votes
  • June 25, 2025Meeting date

Results at a glance

Meeting of June 25, 2025: 4 items on KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 27, 2025: 2 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (12.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KYMERA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by KYMERA THERAPEUTICS INC.

These tallies are KYMERA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KYMERA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 25, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jeffrey Albers, J.D., MBA 55,765,189---- 3,142,2512,748,381 95%Passed (calculated)—
Elect Director: Felix J. Baker, Ph.D. 51,745,887---- 7,161,5532,748,381 88%Passed (calculated)—
2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers 54,364,8804,531,41311,147 --2,748,381 92%Approved—
3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm 61,644,7254,7686,328 --0 99.9%Approved—

Source: KYMERA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 27, 2025 — read the filing on EDGAR.

How asset managers voted at the KYMERA THERAPEUTICS INC. 2024-2025 meeting

193 asset managers disclosed a vote on at least one KYMERA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Felix J. Baker, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 51,745,887WITHHELD: 7,161,553
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Felix J. Baker, Ph.D.

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Felix J. Baker, Ph.D.”): 51,745,887 for, 7,161,553 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 20,153,415 for, 1,280,898 withheld, 1,284,444 abstained.

FOR
FOR: 20,153,415ABSTAIN: 1,284,444WITHHOLD: 1,280,898
Largest asset managers voting on “To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shar” at KYMERA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,142,7750 00For
T. Rowe Price4,957,4250 00For
Fidelity3,060,2200 017,284For
BlackRock00 1,168,1880Abstain
Capital Group1,033,7820 00For
MUTUAL FUND SERIES TRUST525,1380 00For
MFS00 0447,732Withhold
Charles Schwab386,6090 00For
Prudential/PGIM274,1950 04,494For
State Street7260 0248,648Withhold
Hartford237,6960 00For
Equitable19,1440 0120,330Mixed
TIAA110,7060 00For
DRIEHAUS MUTUAL FUNDS00 079,262Withhold
Pacific Life00 070,539Withhold
John Hancock49,9430 16,8390Mixed
Lincoln Financial00 065,919Withhold
Yiheng Capital Management, L.P.63,8540 00For
Northwestern Mutual62,5820 00For
QUANTITATIVE MASTER SERIES LLC00 52,0040Abstain
Brighthouse47,0570 01For
Transamerica43,2630 00For
Victory Capital8390 039,981Withhold
Harbor ETF Trust30,9590 00For
Global X28,3020 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Elect Director: Jeffrey Albers, J.D., MBA

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 55,765,189WITHHELD: 3,142,251
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Jeffrey Albers, J.D., MBA

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Albers, J.D., MBA”): 55,765,189 for, 3,142,251 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 21,809,989 for, 854,124 withheld, 54,644 abstained.

FOR
FOR: 21,809,989ABSTAIN: 54,644WITHHOLD: 854,124
Largest asset managers voting on “To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shar” at KYMERA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,142,7750 00For
T. Rowe Price4,957,4250 00For
Fidelity3,077,5040 00For
BlackRock1,168,1880 00For
Capital Group1,033,7820 00For
MUTUAL FUND SERIES TRUST525,1380 00For
MFS00 0447,732Withhold
Charles Schwab386,6090 00For
Prudential/PGIM274,1950 04,494For
State Street249,0540 0320For
Hartford237,6960 00For
Equitable94,4840 044,990Mixed
TIAA110,7060 00For
DRIEHAUS MUTUAL FUNDS00 079,262Withhold
Pacific Life14,6350 055,904Mixed
John Hancock49,9430 16,8390Mixed
Lincoln Financial34,7000 031,219Mixed
Yiheng Capital Management, L.P.63,8540 00For
Northwestern Mutual62,5820 00For
QUANTITATIVE MASTER SERIES LLC52,0040 00For
Brighthouse47,0570 01For
Transamerica43,2630 00For
Victory Capital8390 039,981Withhold
Harbor ETF Trust30,9590 00For
Global X28,3020 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 54,364,880AGAINST: 4,531,413

Prior year: 97.1% for (June 18, 2024 meeting) ▼ 4.8 pts

Details: description as filed, official tally, votes by 193 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers; and

KYMERA THERAPEUTICS INC.’s own tally for this item (“2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers”): 54,364,880 for, 4,531,413 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 65 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers; and” at KYMERA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,142,370405 00For
T. Rowe Price4,957,4250 00For
Fidelity3,077,5040 00For
BlackRock1,168,1880 00For
Capital Group01,033,782 00Against
MUTUAL FUND SERIES TRUST525,1380 00For
MFS0447,732 00Against
Charles Schwab386,6090 00For
Prudential/PGIM1,284277,405 00Against
State Street249,3740 00For
Hartford237,6960 00For
Equitable139,4740 00For
TIAA110,7060 00For
DRIEHAUS MUTUAL FUNDS79,2620 00For
Pacific Life14,63555,904 00Mixed
John Hancock66,7820 00For
Lincoln Financial64,4441,475 00For
Northwestern Mutual62,5820 00For
QUANTITATIVE MASTER SERIES LLC52,0040 00For
Brighthouse47,0580 00For
Transamerica43,2630 00For
Victory Capital40,8200 00For
Harbor ETF Trust30,9590 00For
Global X028,302 00Against
AIG/SunAmerica26,9690 00For

Fund voting reports, all 65 managers: 20,716,357 for, 1,932,752 against, 5,794 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 146 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers; and” at KYMERA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price6,564,5190 00For
BAKER BROS. ADVISORS LP5,995,9290 00For
Wellington5,390,4490 00For
Atlas Venture Life Science Advisors, LLC4,896,4620 00For
BVF INC/IL4,607,9550 00For
Fidelity4,104,2920 00For
Siren, L.L.C.2,829,9800 00For
Avoro Capital Advisors LLC2,791,2090 00For
BlackRock1,487,75094 00For
GEODE CAPITAL MANAGEMENT, LLC1,101,0870 00For
State Street1,088,5490 00For
Capital Research Global Investors01,033,782 00Against
Redmile Group, LLC0983,413 00Against
DEERFIELD MANAGEMENT COMPANY, L.P.593,0000 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/0503,636 00Against
Rock Springs Capital Management LP464,4490 00For
JENNISON ASSOCIATES LLC0418,727 00Against
BRAIDWELL LP392,7640 00For
Charles Schwab386,9520 00For
DRIEHAUS CAPITAL MANAGEMENT LLC263,6730 00For
Northern Trust226,2460 00For
UBS0197,956 00Against
Janus Henderson149,2140 00For
Foresite Capital Management VI LLC146,3320 00For
Vanguard139,0480 00For

Institutional-manager reports, all 146 managers: 44,375,000 for, 3,783,974 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of the Company's Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 61,644,725AGAINST: 4,768

Prior year: 100.0% for (June 18, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

KYMERA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 61,644,725 for, 4,768 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 22,712,699 for, 264 against, 5,794 abstained.

FOR
FOR: 22,712,699AGAINST: 264ABSTAIN: 5,794
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at KYMERA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,142,7750 00For
T. Rowe Price4,957,4250 00For
Fidelity3,077,5040 00For
BlackRock1,168,1880 00For
Capital Group1,033,7820 00For
MUTUAL FUND SERIES TRUST525,1380 00For
MFS447,7320 00For
Charles Schwab386,6090 00For
Prudential/PGIM278,6890 00For
State Street249,3740 00For
Hartford237,6960 00For
Equitable139,4740 00For
TIAA110,7060 00For
DRIEHAUS MUTUAL FUNDS79,2620 00For
Pacific Life70,5390 00For
John Hancock66,7820 00For
Lincoln Financial65,9190 00For
Yiheng Capital Management, L.P.63,8540 00For
Northwestern Mutual62,5820 00For
QUANTITATIVE MASTER SERIES LLC52,0040 00For
Brighthouse47,0580 00For
Transamerica43,2630 00For
Victory Capital40,8200 00For
Harbor ETF Trust30,9590 00For
Global X28,3020 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Largest KYMERA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 65,112,714 shares outstanding at the time of that meeting.

Fund voting reports: top KYMERA THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 14.04%
2T. Rowe Price 7.61%
3Fidelity 4.73%
4BlackRock 1.79%
5Capital Group 1.59%
6MUTUAL FUND SERIES TRUST 0.81%
7MFS 0.69%
8Charles Schwab 0.59%
9Prudential/PGIM 0.43%
10State Street 0.38%
Institutional-manager reports: top KYMERA THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1T. Rowe Price 10.08%
2BAKER BROS. ADVISORS LP 9.21%
3Wellington 8.28%
4Atlas Venture Life Science Advisors, LLC 7.52%
5BVF INC/IL 7.08%
6Fidelity 6.30%
7Siren, L.L.C. 4.35%
8Avoro Capital Advisors LLC 4.29%
9BlackRock 2.29%
10GEODE CAPITAL MANAGEMENT, LLC 1.69%

Reported KYMERA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KYMERA THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Avoro Capital Advisors LLC6,727,263 10.33%Proxy statement (DEF 14A), proxy filed April 29, 2025
T. Rowe Price6,702,450 10.29%Form 13F, quarter ended March 31, 2025
Entities affiliated with BVF Partners L.P.6,526,900 10.02%Proxy statement (DEF 14A), proxy filed April 29, 2025
Entities affiliated with Baker Bros. Advisors LP6,008,373 9.23%Proxy statement (DEF 14A), proxy filed April 29, 2025
Felix Baker, Ph.D.6,008,373 9.23%Proxy statement (DEF 14A), proxy filed April 29, 2025
T. Rowe Price Investment Management, Inc.5,460,257 8.39%Schedule 13G, filed May 15, 2026
Wellington Management Group LLP5,307,326 8.15%Proxy statement (DEF 14A), proxy filed April 29, 2025
BVF PARTNERS L P/IL5,237,151 8.04%Schedule 13D, filed June 26, 2026
Vanguard Group5,231,392 8.03%Form 13F, quarter ended March 31, 2025
FMR LLC5,109,141 7.85%Proxy statement (DEF 14A), proxy filed April 29, 2025

Percentages above are of 65,112,714 shares outstanding, as reported by KYMERA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KYMERA THERAPEUTICS INC.'s shareholder meeting held June 25, 2025, in the 2024-2025 proxy season, 193 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,039 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — KYMERA THERAPEUTICS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KYMERA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KYMERA THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KYMERA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “KYMERA THERAPEUTICS (KYMR) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/kymera-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.